US Patent 7,799,897: Stellara Biosimilar and Biosimilar Market Impact
US Patent 7,799,897, granted to Johnson & Johnson and subsequently licensed to Janssen Biotech Inc., covers a humanized monoclonal antibody that targets the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23). This antibody is the active ingredient in Stelara (ustekinumab). The patent's expiration is a critical inflection point for the biosimilar market, particularly for therapies targeting autoimmune diseases.
What are the Key Claims of US Patent 7,799,897?
The patent's primary claims focus on the composition of matter for the antibody itself, methods of producing the antibody, and its therapeutic use.
Composition of Matter Claims
The core of the patent lies in its claims defining the specific humanized monoclonal antibody targeting the p40 subunit of IL-12 and IL-23. These claims would typically encompass:
- The antibody itself, characterized by its specific amino acid sequence or complementary determining regions (CDRs).
- Antibody variants or fragments that retain the binding and inhibitory activity of the parent antibody.
- Compositions comprising the antibody, including pharmaceutical formulations for administration.
For instance, claims might define the antibody by its heavy and light chain variable region sequences, or by specific CDR sequences essential for p40 binding. Specific examples of claimed sequences are found within the patent's detailed specification.
Method of Production Claims
These claims cover processes for manufacturing the antibody. This can include:
- Methods for producing the antibody in host cells, such as mammalian cell lines (e.g., CHO cells).
- Specific cell culture conditions or purification techniques employed.
- Processes for generating the nucleic acid sequences encoding the antibody.
The precise details of these manufacturing methods are elaborated in the patent's description, providing a roadmap for creating the active pharmaceutical ingredient.
Therapeutic Use Claims
The patent asserts the utility of the antibody in treating specific conditions mediated by IL-12 and IL-23 signaling. These include:
- Treatment of inflammatory diseases such as plaque psoriasis.
- Treatment of psoriatic arthritis.
- Treatment of Crohn's disease.
- Treatment of ulcerative colitis.
The patent details the administration of the antibody and its efficacy in ameliorating symptoms associated with these conditions.
What is the Patent Landscape for Stelara (Ustekinumab)?
US Patent 7,799,897 is one of several patents protecting Stelara. The broader patent landscape includes patents covering:
- Formulations: Specific ways the drug is prepared for administration, such as subcutaneous injection formulations with specific excipients for stability and delivery.
- Manufacturing Processes: Alternative or improved methods for producing the antibody, potentially offering cost advantages or higher yields.
- Methods of Treatment: New indications or specific patient populations for which the drug can be used.
- Polymorphs and Crystal Forms: Specific solid-state forms of the antibody that may have different stability or manufacturing characteristics.
A comprehensive understanding of the patent landscape requires analyzing all granted patents and pending applications related to ustekinumab, including their expiration dates and potential for infringement.
How Does the Expiration of US Patent 7,799,897 Impact the Biosimilar Market?
The expiration of key patents, including US Patent 7,799,897, is a primary driver for the entry of biosimilars. For Stelara, this means:
- Increased Competition: The expiration clears a significant hurdle for biosimilar manufacturers to gain regulatory approval and market entry.
- Price Reduction: Biosimilar competition is expected to lead to substantial price reductions for ustekinumab therapies, increasing patient access and reducing healthcare system costs.
- Market Share Diversification: The availability of biosimilars will allow for a wider range of therapeutic options and potentially shift market share away from the reference product.
Several companies have been developing ustekinumab biosimilars in anticipation of patent expiries. These include, but are not limited to, Amgen, Celltrion Healthcare, and Samsung Bioepis. The timeline for biosimilar launches is influenced by patent litigation and regulatory review processes.
What is the Anticipated Market Impact of Ustekinumab Biosimilars?
The introduction of ustekinumab biosimilars is projected to have a significant economic impact on the pharmaceutical market, particularly within the immunology sector.
Sales of Stelara and Projected Biosimilar Revenue
Stelara generated approximately $9.13 billion in global sales in 2022 [1]. This substantial revenue stream highlights the market opportunity for biosimilar developers. Projections for the ustekinumab biosimilar market vary but generally indicate a multi-billion dollar opportunity within a few years of widespread launch. For example, analysis by Evaluate Vantage suggests the market for ustekinumab biosimilars could reach several billion dollars annually.
Impact on Psoriasis, Crohn's Disease, and Ulcerative Colitis Treatment
- Plaque Psoriasis: Stelara is a highly effective treatment for moderate to severe plaque psoriasis, offering significant relief to patients. Biosimilars will provide more affordable access to this therapeutic option.
- Psoriatic Arthritis: The drug's efficacy in managing joint inflammation and skin symptoms makes it a crucial treatment for psoriatic arthritis. Biosimilars are expected to broaden access for this patient population.
- Crohn's Disease and Ulcerative Colitis: For inflammatory bowel diseases, Stelara offers a targeted approach by inhibiting IL-12 and IL-23. Biosimilars will offer cost-effective alternatives for long-term management of these chronic conditions.
The availability of biosimilars may also encourage the use of ustekinumab earlier in the treatment algorithm for these diseases, as cost becomes less of a barrier.
Competitive Landscape and Differentiation Strategies
Biosimilar developers compete primarily on price and market access. Key strategies include:
- Cost-Effective Manufacturing: Optimizing production processes to achieve lower manufacturing costs.
- Strategic Partnerships: Collaborating with pharmaceutical companies for distribution and marketing in specific regions.
- Early Market Entry: Securing regulatory approvals and launching swiftly after patent expiry.
- Interchangeability Designation: For biosimilars approved as interchangeable with the reference product, they can be substituted by pharmacists without prescriber intervention, potentially accelerating uptake.
The reference product holder, typically Janssen, may employ strategies to retain market share, such as price adjustments, enhanced patient support programs, or highlighting specific advantages of the originator product.
What is the Regulatory Pathway for Ustekinumab Biosimilars?
Biosimilars in the United States follow a regulatory pathway established by the Biologics Price Competition and Innovation Act (BPCIA) of 2010, overseen by the Food and Drug Administration (FDA).
FDA Approval Process
To gain FDA approval, a biosimilar must demonstrate:
- Analytical Studies: Extensive studies comparing the biosimilar to the reference product (Stelara) to show high similarity in terms of structure, function, and purity.
- Animal Studies: If necessary, to assess immunogenicity and toxicity.
- Clinical Studies: To evaluate pharmacokinetic and pharmacodynamic profiles and to confirm the absence of clinically meaningful differences in safety and efficacy compared to the reference product. This often includes a totality of evidence approach.
The FDA's rigorous review ensures that biosimilars meet the same standards of safety, purity, and potency as the reference product.
Interchangeability Designation
A biosimilar can seek an "interchangeability" designation from the FDA. This requires demonstrating that the biosimilar can be substituted for the reference product without a change in the expected safety, efficacy, and quality of the product. This designation is crucial as it allows for pharmacy-level substitution, similar to generics for small-molecule drugs. Companies like Amgen have pursued interchangeability for their ustekinumab biosimilar, PF-06826332 (Adbysg™).
Key Dates and Milestones
- Patent Expiration: US Patent 7,799,897 has expired, along with other key patents protecting Stelara. This date is a critical trigger for biosimilar development and launch.
- Regulatory Filings: Companies initiate biosimilar development and submit applications to regulatory agencies prior to patent expiry.
- FDA Approval: The FDA reviews these applications. Approval dates for ustekinumab biosimilars will vary by applicant.
- Market Launch: Following approval, biosimilar manufacturers launch their products into the market.
Understanding these timelines is essential for strategic planning in the pharmaceutical industry.
Key Takeaways
- US Patent 7,799,897, covering the composition and therapeutic use of ustekinumab (Stelara), has expired.
- This patent expiration, along with others in the Stelara patent portfolio, facilitates the entry of biosimilars into the market.
- Biosimilar competition is expected to significantly reduce the cost of ustekinumab therapies, improving patient access for conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
- The global market for Stelara exceeds $9 billion annually, presenting a substantial revenue opportunity for biosimilar manufacturers.
- Biosimilar development and approval are governed by strict FDA guidelines, requiring extensive analytical, animal, and clinical studies to demonstrate high similarity to the reference product.
- Interchangeability designation, if granted by the FDA, can further accelerate biosimilar uptake by allowing pharmacy-level substitution.
Frequently Asked Questions
-
When did US Patent 7,799,897 expire?
US Patent 7,799,897 expired on October 15, 2024.
-
Which diseases are treated by the antibody covered by US Patent 7,799,897?
The antibody covered by US Patent 7,799,897 is used to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
-
What is the key target of the antibody described in US Patent 7,799,897?
The antibody targets the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23).
-
What is the significance of patent expiration for pharmaceutical products like Stelara?
Patent expiration allows for the development and market entry of biosimilar versions of the drug, leading to increased competition and lower prices.
-
Can a ustekinumab biosimilar be substituted for Stelara by a pharmacist without a doctor's specific authorization?
A biosimilar can only be substituted by a pharmacist without a doctor's specific authorization if it has received an "interchangeability" designation from the FDA.
Citations
[1] Johnson & Johnson. (2023). Johnson & Johnson reports Q4 and full year 2022 results. Johnson & Johnson Investor Relations. Retrieved from https://www.jnj.com/investor/press-releases/johnson-johnson-reports-q4-and-full-year-2022-results
